New immune cell therapy targets tough pancreatic cancer
NCT ID NCT07480928
Summary
This early-stage trial is testing a new type of treatment using specially engineered immune cells, called CAR-NK cells, for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The study aims to find a safe dose and see if the treatment can shrink tumors in patients whose cancer has grown despite standard treatments. Participants will receive cells designed to attack their cancer based on specific markers found on their tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.